[go: up one dir, main page]

AR084315A1 - Anticuerpos anti-notch1 - Google Patents

Anticuerpos anti-notch1

Info

Publication number
AR084315A1
AR084315A1 ARP110104711A AR084315A1 AR 084315 A1 AR084315 A1 AR 084315A1 AR P110104711 A ARP110104711 A AR P110104711A AR 084315 A1 AR084315 A1 AR 084315A1
Authority
AR
Argentina
Prior art keywords
antibodies
region
notch1
pharmaceutical compositions
notch1 antibodies
Prior art date
Application number
Other languages
English (en)
Inventor
Lioudmila Gennadievna Tchistiakova
Kenneth G Geles
Bin Zhou
Stephen-Gao Yijie Bing
Joel Bard
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of AR084315A1 publication Critical patent/AR084315A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

Anticuerpos que se ligan a Notch1. También provee métodos para preparar los anticuerpos, composiciones farmacéuticas que comprenden estos anticuerpos y métodos para el tratamiento de trastornos con los anticuerpos y las composiciones farmacéuticas.Reivindicación 1: Un anticuerpo que se liga a Notch1, caracterizado porque comprende: una región variable de la cadena pesada que tiene una región CDR1, una región CDR2 y una región CDR3 de la región variable de la cadena pesada que comprende SEQ ID Nº 71.
ARP110104711 2010-12-15 2011-12-15 Anticuerpos anti-notch1 AR084315A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42357810P 2010-12-15 2010-12-15
US201161552578P 2011-10-28 2011-10-28

Publications (1)

Publication Number Publication Date
AR084315A1 true AR084315A1 (es) 2013-05-08

Family

ID=45444674

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104711 AR084315A1 (es) 2010-12-15 2011-12-15 Anticuerpos anti-notch1

Country Status (19)

Country Link
US (2) US9127060B2 (es)
EP (1) EP2651977A2 (es)
JP (1) JP6016800B2 (es)
KR (2) KR101580726B1 (es)
CN (2) CN103547594B (es)
AR (1) AR084315A1 (es)
AU (2) AU2011342799B2 (es)
BR (1) BR112013015122A2 (es)
CA (1) CA2821130C (es)
CO (1) CO6791565A2 (es)
MX (1) MX346995B (es)
NZ (1) NZ611785A (es)
PE (1) PE20141109A1 (es)
PH (2) PH12013501255A1 (es)
RU (1) RU2622083C2 (es)
SA (1) SA111330060B1 (es)
SG (1) SG191039A1 (es)
TW (1) TWI471333B (es)
WO (1) WO2012080926A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539403A (ja) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断および処置するための組成物および方法
WO2008027986A2 (en) 2006-09-01 2008-03-06 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
US8088617B2 (en) 2007-01-24 2012-01-03 Oncomed Pharmaceuticals, Inc. Antibodies that bind the glutamate ligand binding region of Notch1
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
RU2011151287A (ru) 2009-06-18 2013-07-27 Пфайзер Инк. АНТИ Notch-1 АНТИТЕЛА
KR101580726B1 (ko) 2010-12-15 2015-12-29 와이어쓰 엘엘씨 항-노치1 항체
CN104869987B (zh) 2012-09-07 2020-10-16 麻省眼耳医院 用于再生毛细胞和/或支持细胞的方法及组合物
WO2014047426A1 (en) * 2012-09-21 2014-03-27 Oncomed Pharmaceuticals, Inc. Methods of treating hematological malignancies with notch1 antibodies
MX2015005810A (es) 2012-11-07 2015-09-23 Pfizer Anticuerpos anti-notch y conjugados de anticuerpo-farmaco.
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
WO2016069906A1 (en) 2014-10-29 2016-05-06 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
EP3367786A1 (en) * 2015-10-29 2018-09-05 H. Hoffnabb-La Roche Ag Transgenic rabbit with common light chain
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
EP3743057A4 (en) 2018-01-26 2021-11-17 Massachusetts Eye & Ear Infirmary TREATMENT OF HEARING LOSS
CN112243442A (zh) * 2018-04-10 2021-01-19 桑昆血液供给基金会 嵌合Notch受体
CN113365697B (zh) * 2018-09-25 2024-07-19 百进生物科技公司 抗tlr9药剂和组合物及其制备方法和使用方法
KR102499678B1 (ko) * 2020-02-27 2023-02-15 주식회사 베르티스 암의 진단용 조성물
EP4206226A4 (en) * 2020-08-31 2024-10-16 Medytox Inc. Anti-vegf hexameric antibody and composition comprising same
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1117778A2 (en) 1998-10-02 2001-07-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CN1331214A (zh) * 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人缺刻蛋白24.64和编码这种多肽的多核苷酸
WO2002059285A1 (en) 2000-10-27 2002-08-01 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
CN1376686A (zh) * 2001-03-22 2002-10-30 上海博德基因开发有限公司 一种多肽——缺刻蛋白－34.32和编码这种多肽的多核苷酸
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
US20030148954A1 (en) 2001-11-02 2003-08-07 Wisconsin Alumni Research Foundation Agents and methods for modulating activator protein-1-mediated cellular processes
EP1448599A2 (en) 2001-11-14 2004-08-25 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
MXPA04009924A (es) 2002-04-09 2005-07-01 Kyowa Hakko Kogyo Kk Celulas de genoma modificado.
EP1544210A4 (en) 2002-07-18 2006-01-25 Masayasu Okochi NEW NOTCH ORIGIN POLYPEPTIDES AND BIOMARKERS AND REAGENTS FOR WHICH THEY ARE USED
CA2511598C (en) 2002-12-24 2016-09-13 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
AU2004294563B2 (en) 2003-11-26 2009-03-26 Health Research, Inc. Use of notch pathway interfering agents for treatment of plasma cell disorders
US20080220416A1 (en) 2004-05-20 2008-09-11 The Board Of Trustees Of The University Of Illinoi Compositions for Inhibiting Cell Growth and Inducing Apoptosis in Cancer Cells and Methods of Use Thereof
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
AU2005302846A1 (en) * 2004-11-10 2006-05-18 Hubrecht Laboratorium Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
US20080267971A1 (en) 2004-12-21 2008-10-30 Green Larry L Antibodies Directed to Angiopoietin-2 and Uses Thereof
US20080206753A1 (en) 2005-03-04 2008-08-28 The Hospital For Sick Children Methods for Cancer Prognosis
US20070072222A1 (en) 2005-09-23 2007-03-29 Franziska Boess FABP4 as biomarker for toxic effect
US20090305310A1 (en) 2005-11-22 2009-12-10 University Of Vermont And State Agricultural College Methods for Determining Notch Signaling and Uses Thereof
WO2008057144A2 (en) 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
JP2009539403A (ja) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断および処置するための組成物および方法
CN101605815B (zh) * 2006-12-18 2013-11-13 健泰科生物技术公司 拮抗性抗刻缺蛋白3抗体及其在预防和治疗刻缺蛋白3相关疾病中的用途
EP2134356A2 (en) 2007-03-05 2009-12-23 Board of Regents, The University of Texas System Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CA2729306C (en) 2008-07-08 2015-08-18 Oncomed Pharmaceuticals, Inc. Notch-binding agents and antagonists and methods of use thereof
US8834875B2 (en) 2010-01-13 2014-09-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US20110286916A1 (en) * 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
RU2011151287A (ru) * 2009-06-18 2013-07-27 Пфайзер Инк. АНТИ Notch-1 АНТИТЕЛА
RU2012117619A (ru) 2009-09-30 2013-11-10 Дженентек, Инк. ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ДЕЙСТВИЮ АНТАГОНИСТА Notch1, С ПОМОЩЬЮ АНТАГОНИСТА Notch3
WO2012080891A1 (en) 2010-12-15 2012-06-21 Rinat Neuroscience Corp. Anti-notch-1 antibodies
KR101580726B1 (ko) 2010-12-15 2015-12-29 와이어쓰 엘엘씨 항-노치1 항체

Also Published As

Publication number Publication date
AU2011342799A1 (en) 2013-07-04
CN105884896A (zh) 2016-08-24
TWI471333B (zh) 2015-02-01
JP2014503205A (ja) 2014-02-13
PH12013501255A1 (en) 2013-08-05
US20160002331A1 (en) 2016-01-07
SA111330060B1 (ar) 2015-06-04
MX2013006875A (es) 2013-07-05
JP6016800B2 (ja) 2016-10-26
MX346995B (es) 2017-04-06
CA2821130C (en) 2017-11-07
US9127060B2 (en) 2015-09-08
AU2016219704A1 (en) 2016-09-15
TW201302787A (zh) 2013-01-16
WO2012080926A2 (en) 2012-06-21
WO2012080926A3 (en) 2012-10-04
KR101580726B1 (ko) 2015-12-29
HK1194388A1 (zh) 2014-10-17
EP2651977A2 (en) 2013-10-23
AU2011342799B2 (en) 2016-06-09
RU2622083C2 (ru) 2017-06-09
NZ611785A (en) 2015-04-24
CN103547594A (zh) 2014-01-29
PE20141109A1 (es) 2014-09-24
BR112013015122A2 (pt) 2017-05-30
CO6791565A2 (es) 2013-11-14
RU2013126494A (ru) 2015-01-20
CA2821130A1 (en) 2012-06-21
US20130266594A1 (en) 2013-10-10
SG191039A1 (en) 2013-08-30
KR20130108430A (ko) 2013-10-02
KR20150088334A (ko) 2015-07-31
CN103547594B (zh) 2016-05-11
PH12017500864A1 (en) 2017-12-11

Similar Documents

Publication Publication Date Title
AR084315A1 (es) Anticuerpos anti-notch1
ES2543174T3 (es) Composición medicinal para el tratamiento y/o la prevención del cáncer
PE20150002A1 (es) Anticuerpos anti-fcrn
PE20131209A1 (es) Anticuerpos anti-fap
PE20140247A1 (es) Anticuerpos anti-cd38
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
CO6410312A2 (es) Moléculas de anticuerpo que tienen especificidad por humano ox40
AR102554A1 (es) Receptores quiméricos de antígeno anti-cldn y métodos de uso
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
ES2584956T3 (es) Anticuerpos anti-CD40 y usos de los mismos
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
PE20130159A1 (es) Anticuerpos anti-cd40
MX373245B (es) Anticuerpos cd3 humanizados o quiméricos.
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
AR096601A1 (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
EA201400447A1 (ru) АНТИТЕЛА К CD1d
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
PE20141683A1 (es) Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs)

Legal Events

Date Code Title Description
FB Suspension of granting procedure